Beihui Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Beihui Huang has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Juan Li
Department of Haematology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China
5 shared publications - Jingli Gu
Department of Haematology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China
3 shared publications - Junru Liu
Department of Haematology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China
3 shared publications - Lifen Kuang
Department of Haematology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China
2 shared publications - Meilan Chen
Department of Haematology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China
2 shared publications - Xiaozhe Li
Department of Haematology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China
2 shared publications
Latest Publications
- Open Access
- 16 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 8239
The NSDHL/c-Myc/PKM2 Axis Drives Glycolytic Reprogramming and Tumor Growth in Multiple Myeloma
Multiple myeloma (MM) remains largely incurable because of its complex biology and frequent disease relapse. Metabolic reprogramming is increasingly recognized as a critical contributor to MM progression. NAD (P)-dependent steroid dehydrogenase-like protein (NSDHL) has been highlighted as an unfavorable metabolism-related prognostic gene in plasma cell myeloma, but its functional significance and metabolic role in MM remain unclear. Publicly available MM transcriptomic datasets and the MMRF-CoMMpass cohort were analyzed to evaluate NSDHL expression and its clinical relevance. Cell proliferation was assessed using CCK-8 assays, while glucose consumption, lactate production, and extracellular acidification rate were measured to evaluate glycolytic activity. RNA sequencing was performed following NSDHL knockdown. NSDHL was upregulated in MM and associated with advanced disease stage and poor overall survival. NSDHL knockdown suppressed MM cell proliferation and glycolytic activity. Mechanistically, NSDHL reduced c-Myc phosphorylation at T58 while promoting phosphorylation at S62, thereby inhibiting proteasome-dependent degradation of c-Myc and stabilizing the protein. Stabilized c-Myc subsequently enhanced the transcriptional expression of Pyruvate kinase M2 (PKM2), leading to increased glycolysis. Our data reveal a novel NSDHL/c-Myc/PKM2 regulatory axis that drives glycolytic reprogramming and MM cell proliferation, highlighting NSDHL as a potential prognostic biomarker and therapeutic target in MM.
- 16 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 8239
Open AccessThe NSDHL/c-Myc/PKM2 Axis Drives Glycolytic Reprogramming and Tumor Growth in Multiple Myeloma
Multiple myeloma (MM) remains largely incurable because of its complex biology and frequent disease relapse. Metabolic reprogramming is increasingly recognized as a critical contributor to MM progression. NAD (P)-dependent steroid dehydrogenase-like protein (NSDHL) has been highlighted as an unfavorable metabolism-related prognostic gene in plasma cell myeloma, but its functional significance and metabolic role in MM remain unclear. Publicly available MM transcriptomic datasets and the MMRF-CoMMpass cohort were analyzed to evaluate NSDHL expression and its clinical relevance. Cell proliferation was assessed using CCK-8 assays, while glucose consumption, lactate production, and extracellular acidification rate were measured to evaluate glycolytic activity. RNA sequencing was performed following NSDHL knockdown. NSDHL was upregulated in MM and associated with advanced disease stage and poor overall survival. NSDHL knockdown suppressed MM cell proliferation and glycolytic activity. Mechanistically, NSDHL reduced c-Myc phosphorylation at T58 while promoting phosphorylation at S62, thereby inhibiting proteasome-dependent degradation of c-Myc and stabilizing the protein. Stabilized c-Myc subsequently enhanced the transcriptional expression of Pyruvate kinase M2 (PKM2), leading to increased glycolysis. Our data reveal a novel NSDHL/c-Myc/PKM2 regulatory axis that drives glycolytic reprogramming and MM cell proliferation, highlighting NSDHL as a potential prognostic biomarker and therapeutic target in MM.
- Open Access
The Prognostic Significance of Dynamic Monitoring of Minimal Residual Disease Status in Patients with Multiple Myeloma: A Real-World Study
Background: Minimal residual disease (MRD) is an established prognostic factor in multiple myeloma (MM), but the significance of dynamic MRD changes before and after autologous stem cell transplantation (ASCT) remains unclear. Methods: We retrospectively analysed 335 newly diagnosed MM patients who underwent upfront ASCT. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan–Meier method and compared using the log-rank test. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence interval (CI), adjusting for clinical risk factors. Results: Patients were classified as having persistent MRD negativity (n = 82, 24.5%), MRD− to MRD+ conversion (n = 40, 11.9%), MRD+ to MRD− conversion (n = 168, 50.1%), or persistent MRD positivity (n = 45, 13.4%). Median OS was not reached: 105, 131, and 87 months for the groups (p < 0.001); and PFS was not reached: 50, 71, and 38 months (p < 0.001). In multivariable analysis, persistent MRD positivity (HR, 4.762; 95% CI, 2.151–10.546; p < 0.001) and MRD− to MRD+ conversion (HR, 3.925; 95% CI, 1.791–8.598; p < 0.001) were associated with increased mortality risk compared with persistent MRD negativity, whereas MRD+ to MRD− conversion showed a borderline-significant increase (HR, 1.973; 95% CI, 0.963–4.046; p = 0.063). In addition, similar patterns were observed for PFS. In subgroup analyses, late MRD+ to MRD− conversion was associated with inferior PFS (HR, 1.857; 95% CI, 1.136–3.034; p = 0.014), whereas MRD− to MRD+ conversion showed no differences in OS or PFS (all p > 0.05). Among persistent MRD-positive patients, stable or increasing MRD pattern predicted worse outcomes (HR, 4.397; 95% CI, 1.190–16.240; p = 0.026). Conclusions: Longitudinal MRD trajectories provided independent prognostic information beyond static MRD assessment in MM. Subgroup analyses further suggest that dynamic MRD assessment might help refine risk stratification after ASCT.
Open AccessThe Prognostic Significance of Dynamic Monitoring of Minimal Residual Disease Status in Patients with Multiple Myeloma: A Real-World Study
Background: Minimal residual disease (MRD) is an established prognostic factor in multiple myeloma (MM), but the significance of dynamic MRD changes before and after autologous stem cell transplantation (ASCT) remains unclear. Methods: We retrospectively analysed 335 newly diagnosed MM patients who underwent upfront ASCT. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan–Meier method and compared using the log-rank test. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence interval (CI), adjusting for clinical risk factors. Results: Patients were classified as having persistent MRD negativity (n = 82, 24.5%), MRD− to MRD+ conversion (n = 40, 11.9%), MRD+ to MRD− conversion (n = 168, 50.1%), or persistent MRD positivity (n = 45, 13.4%). Median OS was not reached: 105, 131, and 87 months for the groups (p < 0.001); and PFS was not reached: 50, 71, and 38 months (p < 0.001). In multivariable analysis, persistent MRD positivity (HR, 4.762; 95% CI, 2.151–10.546; p < 0.001) and MRD− to MRD+ conversion (HR, 3.925; 95% CI, 1.791–8.598; p < 0.001) were associated with increased mortality risk compared with persistent MRD negativity, whereas MRD+ to MRD− conversion showed a borderline-significant increase (HR, 1.973; 95% CI, 0.963–4.046; p = 0.063). In addition, similar patterns were observed for PFS. In subgroup analyses, late MRD+ to MRD− conversion was associated with inferior PFS (HR, 1.857; 95% CI, 1.136–3.034; p = 0.014), whereas MRD− to MRD+ conversion showed no differences in OS or PFS (all p > 0.05). Among persistent MRD-positive patients, stable or increasing MRD pattern predicted worse outcomes (HR, 4.397; 95% CI, 1.190–16.240; p = 0.026). Conclusions: Longitudinal MRD trajectories provided independent prognostic information beyond static MRD assessment in MM. Subgroup analyses further suggest that dynamic MRD assessment might help refine risk stratification after ASCT.
- Open Access
- 16 June 2025
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 23 (1) , 1-17
Integrative analysis of bulk and single-cell gene expression profiles to identify bone marrow mesenchymal cell heterogeneity and prognostic significance in multiple myeloma
Background: Multiple myeloma is a hematologic malignancy characterized by complex interactions within the tumor microenvironment, where mesenchymal stem cells (MSCs) contribute significantly to disease progression, immune suppression, and drug resistance. Methods: This study investigated the heterogeneity of MSCs in multiple myeloma using single-cell RNA sequencing (10X) and bulk transcriptomic data. Further analysis was performed by Seurat, SCENIC, CellChat. GSE4581 and GSE136337 were used as training set and validation set to construct a newly described prognostic model through COX and LASSO. Results: By analyzing bone marrow samples from healthy donors and multiple myeloma patients at different Revised International Staging System (R-ISS) stages, this study identified distinct MSC subpopulations, including osteogenic, angiogenic, immune regulatory, and multipotent clusters, each of which plays unique roles in the tumor microenvironment. Interestingly, we found a unique subclone with upregulated expression of high mobility group proteins, these MSC exert a strong regulatory effect, which was defined as “HMGhMSC”. Conclusions: Our findings reveal that the proportion of osteogenic MSCs, which are crucial for bone health, decreases as the disease progresses, which is correlated with the bone lysis commonly observed in advanced multiple myeloma. Additionally, immune regulatory MSCs contribute to the formation of an immunosuppressive microenvironment, promoting tumor immune evasion. A prognostic model based on HMGhMSC subpopulations was developed, which demonstrated that these cells have significant potential as therapeutic targets for improving the prognosis and developing treatments for bone disease in multiple myeloma patients.
- 16 June 2025
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 23 (1) , 1-17
Open AccessIntegrative analysis of bulk and single-cell gene expression profiles to identify bone marrow mesenchymal cell heterogeneity and prognostic significance in multiple myeloma
Background: Multiple myeloma is a hematologic malignancy characterized by complex interactions within the tumor microenvironment, where mesenchymal stem cells (MSCs) contribute significantly to disease progression, immune suppression, and drug resistance. Methods: This study investigated the heterogeneity of MSCs in multiple myeloma using single-cell RNA sequencing (10X) and bulk transcriptomic data. Further analysis was performed by Seurat, SCENIC, CellChat. GSE4581 and GSE136337 were used as training set and validation set to construct a newly described prognostic model through COX and LASSO. Results: By analyzing bone marrow samples from healthy donors and multiple myeloma patients at different Revised International Staging System (R-ISS) stages, this study identified distinct MSC subpopulations, including osteogenic, angiogenic, immune regulatory, and multipotent clusters, each of which plays unique roles in the tumor microenvironment. Interestingly, we found a unique subclone with upregulated expression of high mobility group proteins, these MSC exert a strong regulatory effect, which was defined as “HMGhMSC”. Conclusions: Our findings reveal that the proportion of osteogenic MSCs, which are crucial for bone health, decreases as the disease progresses, which is correlated with the bone lysis commonly observed in advanced multiple myeloma. Additionally, immune regulatory MSCs contribute to the formation of an immunosuppressive microenvironment, promoting tumor immune evasion. A prognostic model based on HMGhMSC subpopulations was developed, which demonstrated that these cells have significant potential as therapeutic targets for improving the prognosis and developing treatments for bone disease in multiple myeloma patients.
- Open Access
- 9 January 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (1) , 145
Early Identification of the Non-Transplanted Functional High-Risk Multiple Myeloma: Insights from a Predictive Nomogram
Background: Patients with multiple myeloma (MM) who have a suboptimal response to induction therapy or early relapse are classified as functional high-risk (FHR) patients and have been shown to have a dismal prognosis. The aim of this study was to establish a predictive nomogram for patients with non-transplanted FHR MM. Materials and Methods: The group comprised 215 patients in our center between 1 January 2006 and 1 March 2024. To identify independent risk factors, univariate and multivariate logistic regression analyses were performed, and a nomogram was constructed to predict non-transplant FHR MM. To evaluate the nomogram’s predictive accuracy, we utilized bias-corrected AUC, calibration curves, decision curve analysis (DCA), and clinical impact curves (CIC). Results: Multivariate logistic regression demonstrated that younger age at onset, a higher proportion of LDH (more than 220 U/L), pattern A + C of M protein decline patterns, a lower proportion of patients with induction treatment efficacy than VGPR, and those undergoing maintenance therapies were independent risk factors for patients with non-transplanted FHR MM. The AUC scores for the training and internal validation groups were 0.940 (95% CI 0.893–0.986) and 0.978 (95% CI 0.930–1.000). DCA and CIC curves were utilized to further verify the clinical efficacy of the nomogram. Conclusions: We developed a nomogram that enables early prediction of non-transplant FHR MM patients. Younger age at onset, LDH ≥ 220 U/L, an A + C pattern of M-protein decline, and induction therapy efficacy not reaching VGPR are more likely to be FHR MM patients. Patients who do not undergo maintenance therapy are prone to early progression or relapse.
- 9 January 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (1) , 145
Open AccessEarly Identification of the Non-Transplanted Functional High-Risk Multiple Myeloma: Insights from a Predictive Nomogram
Background: Patients with multiple myeloma (MM) who have a suboptimal response to induction therapy or early relapse are classified as functional high-risk (FHR) patients and have been shown to have a dismal prognosis. The aim of this study was to establish a predictive nomogram for patients with non-transplanted FHR MM. Materials and Methods: The group comprised 215 patients in our center between 1 January 2006 and 1 March 2024. To identify independent risk factors, univariate and multivariate logistic regression analyses were performed, and a nomogram was constructed to predict non-transplant FHR MM. To evaluate the nomogram’s predictive accuracy, we utilized bias-corrected AUC, calibration curves, decision curve analysis (DCA), and clinical impact curves (CIC). Results: Multivariate logistic regression demonstrated that younger age at onset, a higher proportion of LDH (more than 220 U/L), pattern A + C of M protein decline patterns, a lower proportion of patients with induction treatment efficacy than VGPR, and those undergoing maintenance therapies were independent risk factors for patients with non-transplanted FHR MM. The AUC scores for the training and internal validation groups were 0.940 (95% CI 0.893–0.986) and 0.978 (95% CI 0.930–1.000). DCA and CIC curves were utilized to further verify the clinical efficacy of the nomogram. Conclusions: We developed a nomogram that enables early prediction of non-transplant FHR MM patients. Younger age at onset, LDH ≥ 220 U/L, an A + C pattern of M-protein decline, and induction therapy efficacy not reaching VGPR are more likely to be FHR MM patients. Patients who do not undergo maintenance therapy are prone to early progression or relapse.
- Open Access
- 25 February 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (3) , 412
Clinical Characteristics and Prognosis of Secondary Acute Lymphoblastic Leukemia in Patients with Multiple Myeloma during Long-Term Thalidomide Maintenance
Background: Secondary primary malignancies (SPM) have attracted increasing attention with the application of autologous hematopoietic stem cell transplantation (ASCT) and novel agents in multiple myeloma (MM). Secondary acute lymphoblastic leukemia (sALL) has rarely been reported, and the clinical characteristics and prognosis of sALL have not been described in detail. Methods: We retrospectively enrolled 179 consecutive newly diagnosed multiple myeloma (NDMM) patients undergoing bortezomib-based induction regimens followed by upfront ASCT and maintenance therapy from December 2006 to April 2018 in our center. Results: The median follow-up interval was 69.1 months, and 12 patients (6.7%) developed sALL during maintenance therapy. The median time from the diagnosis of MM to the occurrence of sALL was 51.1 (31.7–91.5) months. All sALL patients received thalidomide as maintenance therapy before the onset of sALL, and the median duration of thalidomide maintenance was 39.5 (24–74) months. The cumulative incidence of sALL was 6.6% and 11.2% at 5 and 10 years after the diagnosis of MM, respectively. All sALL patients presented with a B-cell immunophenotype accompanied by myeloid antigen expression according to flow cytometry analysis, and the BCR/ABL fusion gene was all negative. Only one patient had evidence of active MM, and the other patients were in stable status at the time of the diagnosis of sALL. The prognosis of most sALL patients was very poor, and the median overall survival time was 11.9 (1.1–51.2) months since the diagnosis of sALL. Conclusions: sALL should be considered for MM patients who developed unexplained persistent cytopenia while on long-term thalidomide maintenance treatment, particularly if it has been more than 3 years. With the increasing availability of new drugs for MM, thalidomide may be recommended for no more than 3 years. Sequential allogeneic hematopoietic stem cell transplantation was considered as soon as possible after achieving remission in order to achieve a longer survival.
- 25 February 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (3) , 412
Open AccessClinical Characteristics and Prognosis of Secondary Acute Lymphoblastic Leukemia in Patients with Multiple Myeloma during Long-Term Thalidomide Maintenance
Background: Secondary primary malignancies (SPM) have attracted increasing attention with the application of autologous hematopoietic stem cell transplantation (ASCT) and novel agents in multiple myeloma (MM). Secondary acute lymphoblastic leukemia (sALL) has rarely been reported, and the clinical characteristics and prognosis of sALL have not been described in detail. Methods: We retrospectively enrolled 179 consecutive newly diagnosed multiple myeloma (NDMM) patients undergoing bortezomib-based induction regimens followed by upfront ASCT and maintenance therapy from December 2006 to April 2018 in our center. Results: The median follow-up interval was 69.1 months, and 12 patients (6.7%) developed sALL during maintenance therapy. The median time from the diagnosis of MM to the occurrence of sALL was 51.1 (31.7–91.5) months. All sALL patients received thalidomide as maintenance therapy before the onset of sALL, and the median duration of thalidomide maintenance was 39.5 (24–74) months. The cumulative incidence of sALL was 6.6% and 11.2% at 5 and 10 years after the diagnosis of MM, respectively. All sALL patients presented with a B-cell immunophenotype accompanied by myeloid antigen expression according to flow cytometry analysis, and the BCR/ABL fusion gene was all negative. Only one patient had evidence of active MM, and the other patients were in stable status at the time of the diagnosis of sALL. The prognosis of most sALL patients was very poor, and the median overall survival time was 11.9 (1.1–51.2) months since the diagnosis of sALL. Conclusions: sALL should be considered for MM patients who developed unexplained persistent cytopenia while on long-term thalidomide maintenance treatment, particularly if it has been more than 3 years. With the increasing availability of new drugs for MM, thalidomide may be recommended for no more than 3 years. Sequential allogeneic hematopoietic stem cell transplantation was considered as soon as possible after achieving remission in order to achieve a longer survival.